New hope for tough stomach cancers: two drugs team up
NCT ID NCT03686488
Summary
This study tested whether combining two drugs, TAS-102 and ramucirumab, is safe and can help people with advanced stomach or gastroesophageal cancer that has stopped responding to other treatments. It involved 23 patients to see if the combination could help them live longer and control the cancer's growth. The main goal was to measure overall survival and track any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.